Agents that modulate immune checkpoint proteins, such as programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), have become a major strategy in cancer treatment. Advanced melanoma is one of the major targets of immune checkpoint inhibitors (1). Their clinical benefit can be accompanied by immune-related adverse events (irAEs), which affect the skin, gastrointestinal tract, liver, and endocrine system. The endocrine organs of irAEs include pituitary, thyroid, and adrenal glands, as well as other downstream target organs (2). The endocrine irAEs are typically grade 1 or 2 in severity and often present with non-specific symptoms. In particular, isolated adrenocorticotropic hormone (ACTH) deficiency is characterized by general fatigue, appetite loss, weight loss, hypoglycaemia, hypotension, and hyponatraemia. Thus, these adverse effects might be underdiagnosed.

We report here 2 patients with advanced melanoma, who developed isolated ACTH deficiency induced by nivolumab (Nivo). This rare type of irAE should be considered in patients receiving long-term administration of immune checkpoint inhibitors, such as those with advanced melanoma.

CASE REPORTS

**Patient 1.** A 53-year-old Japanese man with a primary nodular melanoma on the left thigh with lymph node metastasis was referred to us and diagnosed as American Joint Committee on Cancer (AJCC) stage IIIB (pT4N3bM0; Breslow tumour thickness, 8 mm; Clark’s level V, with ulceration; and Ki-67 index, approximately 50%). The patient received an extended resection of the primary tumour area followed by administration of weekly PEG-interferon-α, 7 courses, of their cardiac adverse effect, the drugs were discontinued, and the patient received an extended resection of the primary tumour area.

**Patient 2.** A 72-year-old man was diagnosed with AJCC stage IV melanoma (pT3N1M1a(0)), because of metastatic lesions of the left inguinal lymph nodes and the upper field of the right lung. He received surgical removal of the inguinal lymph nodes and lung lesion. Molecular testing for a BRAFV600E mutation was not performed, and he was treated with Nivo, 3 mg/kg, at 2-week intervals. At 28 weeks, he had general fatigue without fever, followed by appetite loss and vomiting. CK and blood eosinophil count fluctuated after initiation of Nivo, and at 44 weeks, his serum sodium level was dramatically decreased to 126 mEq/l. He had weight loss of 13 kg for 3 months.

Endocrinologically, ACTH and urinary free cortisol were within normal limits; however, cortisol (6.3 μg/l) was decreased. TSH, FT3 and FT4 showed normal levels, and anti-Tg, TPO and TR antibodies were negative. ADH, GH, IGF-1, LH, FSH were all within normal ranges. MRI of his pituitary gland exhibited no abnormality in size or tumour lesion. A detailed assessment of anterior pituitary functions with hypothalamic hormone challenges was performed. The results showed a disturbance in the secretion of ACTH in the corticotrophin-releasing hormone (CRH) test (Fig. S1 ). On the other hand, prolactin secretion was intact in the thyrotropin-releasing hormone (TRH) test, and the secretion of GH and LH/FSH was also normal in the GH-releasing peptide-2 (GHRP-2) and LH-releasing hormone (LH-RH) tests, respectively (Fig. S1 ).

His condition was diagnosed as isolated ACTH deficiency. At 36 weeks, he was treated with hydrocortisone, 15 mg daily, which improved muscle pain and general fatigue despite continuing Nivo treatment. At 16 months after initiation of Nivo, neither recurrence nor new metastatic lesion was found.

**DISCUSSION**

A recent cohort study demonstrated that the incidence of endocrine irAE was 12.9% in patients receiving ipilimumab (CTLA-4 inhibitor), Nivo, and/or pembrolizumab (PD-1 inhibitor), and the most common was thyroid dysfunction.

---

1. https://doi.org/10.2340/00015555-2902

---

This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta

Journal Compilation © 2018 Acta Dermato-Venereologica.
(11.1%), with a lower incidence of pituitary dysfunction (1.8%) (3). Other groups also reported that hypopituitarism is more frequently induced by ipilimumab than by Nivo (17.0% vs 1.9%), and they share male preponderance and lack of pituitary MRI abnormality (4, 5). The incidence rate of hypophysitis by pembrolizumab is also as low as 0.9% (6). Furthermore, in the CheckMate-069 trial, it was noted that the incidence of grade 1–2 hypophysitis ranged from 11% in patients treated with combination of Nivo and ipilimumab to 2% in patients treated with ipilimumab alone (7). Thus, an awareness of the symptoms and management of endocrine irAEs may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.

Table I summarizes the reported cases of hypopituitarism induced by Nivo in patients with advanced melanoma (8–14). Eight out of 9 patients, including our 2 cases, are men. The reason for this male preponderance is unknown. In all cases, hypopituitarism was diagnosed as isolated ACTH deficiency and the onset of isolated ACTH deficiency was 8–40 weeks after initiation of Nivo. Hypopituitarism has been reported in melanoma patients, but rarely in patients with lung cancer (15) despite the higher number of Nivo-treated lung cancer patients. Considering that melanoma patients are usually treated with Nivo for a longer period, the length of treatment might contribute to the development of this irAE.

The hypopituitarism of ipilimumab ranges from isolated deficiency to multiple hormone deficiency (4, 5), but our study suggests that Nivo shows only isolated ACTH deficiency. Given that ipilimumab can promote sensitization of CTLs, it is reasonable that this anti-CTLA-4 antibody yield CTLs specific to various pituitary antigenic determinants. On the other hand, Nivo may enhance only the CTL that have already been sensitized in melanoma patients, and antibody-dependent cellular cytotoxicity (ADCC) might operate with specific antibodies. In this context, the presence of autoimmune hypophysitis, also known as primary lymphocytic hypophysitis, provides an explanation. Nivo might render this disorder overt by activating CTLs, possibly with ADCC activity.

Clinically, isolated ACTH deficiency should be borne in mind when melanoma patients treated with immune checkpoint inhibitors develop non-specific, general malaise. Elucidation of its mechanism also may contribute to prediction of this deficiency.

The authors have no conflicts of interest to declare.

REFERENCES


Table I. Reported cases of hypopituitarism in advanced melanoma patients treated with nivolumab (Nivo)

<table>
<thead>
<tr>
<th>Authors</th>
<th>Age, years/ Sex</th>
<th>Stage</th>
<th>Treatment before Nivo</th>
<th>Nivo dose</th>
<th>Prognosis</th>
<th>MRI of pituitary gland</th>
<th>Symptoms and lab hormones</th>
<th>Onset, weeks</th>
<th>Disturbed hormones</th>
<th>Treatment, mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kitajima et al. (8)</td>
<td>39/M</td>
<td>IV</td>
<td>Dacarbazine</td>
<td>2 mg/kg/3w</td>
<td>SD</td>
<td>NP</td>
<td>ACTH, cortisol</td>
<td>39</td>
<td>HC</td>
<td>10</td>
</tr>
<tr>
<td>Okano et al. (9)</td>
<td>50/M</td>
<td>IV</td>
<td>None</td>
<td>2 mg/kg/3w</td>
<td>SD</td>
<td>ND</td>
<td>Slight swelling, GF, AL</td>
<td>18</td>
<td>ACTH, cortisol</td>
<td>100</td>
</tr>
<tr>
<td>Trainer et al. (10)</td>
<td>43/M</td>
<td>IIA</td>
<td>None</td>
<td>3 mg/kg/2w</td>
<td>SD</td>
<td>NP</td>
<td>GF, AL, WL, hypotension</td>
<td>18</td>
<td>ACTH, cortisol</td>
<td>20</td>
</tr>
<tr>
<td>Ishikawa et al. (11)</td>
<td>55/M</td>
<td>IV</td>
<td>Dacarbazine</td>
<td>2 mg/kg/3w</td>
<td>SD</td>
<td>NP</td>
<td>GF, AL, WL, vomiting</td>
<td>12</td>
<td>ACTH, cortisol</td>
<td>30</td>
</tr>
<tr>
<td>Fujiimura et al. (12)</td>
<td>68/M</td>
<td>IV</td>
<td>None</td>
<td>2 mg/kg/3w</td>
<td>PD</td>
<td>NP</td>
<td>ACTH, cortisol</td>
<td>28</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Oda et al. (13)</td>
<td>85/M</td>
<td>IV</td>
<td>None</td>
<td>2 mg/kg/3w</td>
<td>PR</td>
<td>ND</td>
<td>GF, AL</td>
<td>20</td>
<td>ACTH, cortisol</td>
<td>15</td>
</tr>
<tr>
<td>Narahira et al. (14)</td>
<td>76/F</td>
<td>IV</td>
<td>None</td>
<td>2 mg/kg/3w</td>
<td>NA</td>
<td>NP</td>
<td>GF, AL</td>
<td>27</td>
<td>ACTH, cortisol</td>
<td>15</td>
</tr>
<tr>
<td>Our case 1</td>
<td>53/M</td>
<td>IV</td>
<td>Dabrafenib, trametinib</td>
<td>3 mg/kg/2w</td>
<td>SD</td>
<td>NP</td>
<td>GF, muscle pain, high CK</td>
<td>14</td>
<td>ACTH, cortisol</td>
<td>15</td>
</tr>
<tr>
<td>Our case 2</td>
<td>72/M</td>
<td>IV</td>
<td>None</td>
<td>3 mg/kg/2w</td>
<td>PD</td>
<td>NP</td>
<td>GF, AL, hypotension</td>
<td>30</td>
<td>ACTH, cortisol</td>
<td>10–15</td>
</tr>
</tbody>
</table>

SD: stable disease; PD: progressive disease; PR: partial response; NP: nothing particular; ND: not done; NA: not available; GF: general fatigue; AL: appetite loss; WL: weight loss; ACTH: adrenocorticotropic hormone; HC: hydrocortisol.